首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Development of a two-step tier-2 dissolution method for blinded overencapsulated erlotinib tablets using UV fiber optic detection.
【24h】

Development of a two-step tier-2 dissolution method for blinded overencapsulated erlotinib tablets using UV fiber optic detection.

机译:开发了使用紫外线光纤检测的盲法过度封装的厄洛替尼片的两步法第2层溶解方法。

获取原文
获取原文并翻译 | 示例
           

摘要

Measuring dissolution of a comparator drug overencapsulated in a hard gelatin shell is necessary when determining performance of the native and blinded formulations. However, the gelatin in the shell may form cross-links upon storage at stressed conditions, resulting in slow dissolution of the encapsulated drug. The aim of this study was to develop a dissolution approach for a hard-gelatin overencapsulated formulation of a comparator drug, erlotinib, which can overcome cross linking of the capsule shell. In this case, following the USP two-tier dissolution test by simply adding an enzyme did not dissolve the cross-linked capsules because the medium used in the method for erlotinib described in the FDA Dissolution Database contains sodium dodecyl sulfate that inhibits the activity of the enzyme. Changing the method by using different surfactants was not considered acceptable because it is preferable to closely follow the compendial method for the comparator. A two-step tier-2 method was developed as a solution, without significant change to the compendial method conditions. It uses 0.1N HCl + pepsin as the initial medium to help capsule break-up. SDS is added at 15 min after the testing starts to ensure dissolution of the drug. This may be a useful general approach for dealing with cross-linking in over-encapsulated comparators. A UV fiber optic spectrophotometer was used for in situ, real-time detection of the dissolution profile during method development studies. The fast sampling rate available with this type of detection was important in elucidating the events occurring during dissolution and determining the optimal time of the SDS addition.
机译:当确定天然制剂和盲制剂的性能时,有必要测量过量包裹在硬明胶壳中的比较药物的溶出度。但是,在压力条件下储存时,壳中的明胶可能形成交联,导致封装药物的缓慢溶解。这项研究的目的是为比较药厄洛替尼的硬明胶超囊化制剂开发一种溶解方法,该方法可以克服胶囊壳的交联。在这种情况下,仅通过添加酶后进行USP两级溶出度测试并不能溶解交联的胶囊,因为FDA溶出度数据库中所述的厄洛替尼方法所用的介质含有十二烷基硫酸钠,从而抑制了药物的活性。酶。通过使用不同的表面活性剂来改变方法被认为是不可接受的,因为最好严格遵循比较法的药典方法。作为解决方案,开发了一种分两步进行的第2层方法,而对药典方法的条件没有重大更改。它使用0.1N HCl +胃蛋白酶作为初始培养基,以帮助胶囊破裂。在测试开始后15分钟添加SDS,以确保药物溶解。这可能是处理过度封装的比较器中的交叉链接的有用的通用方法。在方法开发研究过程中,使用了紫外分光光度计对溶出曲线进行原位实时检测。这种类型的检测可提供的快速采样速率对于阐明溶解过程中发生的事件以及确定SDS添加的最佳时间非常重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号